Medical hypotheses2021,Vol.1461.DOI:10.1016/j.mehy.2020.110421

Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO(2)Life (R) (M101)

Lupon, Elise Lellouch, Alexandre G. Zal, Franck Cetrulo, Curtis L., Jr. Lantieri, Laurent A.
Medical hypotheses2021,Vol.1461.DOI:10.1016/j.mehy.2020.110421

Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO(2)Life (R) (M101)

Lupon, Elise 1Lellouch, Alexandre G. 2Zal, Franck 3Cetrulo, Curtis L., Jr. 2Lantieri, Laurent A.4
扫码查看

作者信息

  • 1. Univ Toulouse III Paul Sabatier, Dept Plast Surg, Toulouse, France
  • 2. Harvard Med Sch, Vascularized Composite Allotransplantat Lab, Ctr Transplantat Sci, Massachusetts
  • 3. Aeropole Ctr, Dept HEMARINA SA, Biotechnopole, Morlaix, France
  • 4. Univ Paris, European George Pompidou Hosp, Dept Plast Surg, Paris, France
  • 折叠

Abstract

Background: Infection with SARS-CoV-2 is responsible for the COVID-19 crisis affecting the whole world. This virus can provoke acute respiratory distress syndrome (ARDS) leading to overcrowed the intensive care unit (ICU). Over the last months, worldwide experience demonstrated that the ARDS in COVID-19 patients are in many ways "atypical". The mortality rate in ventilated patients is high despite the application of the gold standard treatment (protective ventilation, curare, prone position, inhaled NO). Several studies suggested that the SARS-CoV-2 could interact negatively on red blood cell homeostasis. Furthermore, SarsCov2 creates Reactive Oxygen Species (ROS), which are toxic and generate endothelial dysfunction.

Key words

Hypoxemia/COVID-19/Oxygen Carrier/HEMO2Life/M101/SARS-CoV-2

引用本文复制引用

出版年

2021
Medical hypotheses

Medical hypotheses

SCI
ISSN:0306-9877
被引量2
参考文献量64
段落导航相关论文